Volition Webinar: Unraveling the web of NETs in sepsis

Volition Webinar: Unraveling the web of NETs in sepsis

Associated equity: VolitionRx

VolitionRx is a clinical diagnostics company developing easy-to-use and cost-effective blood tests to diagnose a range of diseases in humans and animals including sepsis and cancer. Diagnostic Nu.Q tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid.

VolitionRx — 4 videos in collection

VolitionRX is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

In this webinar, intensive care specialist and haematology key opinion leader Dr Andrew Retter helps us understand the burden of sepsis and challenges in treatment and patient care, the connection between NETosis and sepsis, the future of tools and treatments, as well as the potential role of NETs in other disease areas, and the role of Volition’s diagnostics tools to address unmet need in the space.

Leading the panel and Q&A session is Soo Romanoff, Managing Director of Healthcare at Edison Group.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free